Disulfiram Protects Against Radiation-Induced Intestinal Injury in Mice

Qingwen Yuan, Renjun Peng, Huijie Yu, Sinian Wang, Zhongmin Chen, Suhe Dong, Wěi Li, Bo Cheng, Qisheng Jiang, Yuwen Cong, Fengsheng Li, Changzheng LiFrontiers in Pharmacology 2022 · DOI

TL;DR

Disulfiram, an existing FDA-approved drug for alcohol deterrence, shows significant promise in protecting against radiation-induced intestinal injury (RIII) in mice. By preserving intestinal stem cells, reducing DNA damage, and promoting regeneration, disulfiram offers a potential new therapeutic strategy for RIII in cancer therapy and nuclear accident scenarios.

What Problem Does This Paper Address?

Radiation therapy, while crucial for cancer treatment, often leads to severe side effects, particularly radiation-induced intestinal injury (RIII). This damage can limit the radiation dose that can be safely administered, hindering treatment efficacy, and can also be a major cause of morbidity and mortality in nuclear disasters. Despite the significant impact of RIII, there are currently no approved drugs specifically for its prevention or treatment. This paper addresses the urgent need for effective radioprotective agents by investigating the potential of disulfiram, a drug already approved for alcohol dependence, as a countermeasure for RIII.

Methods

The researchers employed a multi-faceted approach to evaluate disulfiram's efficacy:

  • Animal Models: Lethally irradiated mice (both total-body irradiation - TBI, and total-abdominal irradiation - TAI) were used to assess survival rates and overall intestinal health.
  • Histological Analysis: Hematoxylin and eosin (H&E) staining was used to examine the structural integrity of the small intestine, focusing on crypt survival and villus height.
  • Cell Proliferation and Regeneration Assays:
    • BrdU (5-Bromo-2'-deoxyuridine) incorporation: This assay measures DNA synthesis, indicating cell proliferation and the ability of crypt cells to regenerate.
  • Phospho-histone H3 staining: This marker identifies cells undergoing mitosis, providing insights into cell cycle progression and proliferation.
  • Stem Cell Tracking:
    • Lgr5-EGFP and Bmi1-CreER lineage tracing: These sophisticated genetic tools were used to track the survival and regenerative capacity of intestinal stem cells (ISCs) after irradiation, both in the presence and absence of disulfiram.
  • Apoptosis Assays:
    • TUNEL (Terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay: Detects DNA fragmentation, a hallmark of apoptosis.
  • Cleaved caspase-3 (CC3) immunohistochemistry: Identifies activated caspase-3, a key executioner protein in the apoptotic pathway.
  • DNA Damage Assessment:
    • γ-H2AX staining: This marker indicates the presence of DNA double-strand breaks (DSBs), a critical type of DNA damage induced by radiation. Both immunohistochemistry (IHC) and Western blotting were used to quantify γ-H2AX levels.
  • Aberrant Mitosis Assessment: H&E staining was used to identify abnormal chromosome segregation during cell division, a sign of genomic instability.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from mouse models and cell cultures.

Key Insights and Ideas

  • Repurposing Existing Drugs: The study highlights the potential of repurposing existing, FDA-approved drugs like disulfiram for new therapeutic applications, which can significantly accelerate the drug development process.
  • Stem Cell Protection is Key: The findings strongly suggest that disulfiram's protective effects are largely mediated by its ability to preserve intestinal stem cells (ISCs), particularly the Lgr5+ population, which are crucial for intestinal repair.
  • Delayed Apoptosis Mitigation: Counterintuitively, disulfiram did not prevent early apoptosis but rather mitigated the delayed apoptosis that occurs later after irradiation, suggesting a role in managing the consequences of severe damage.
  • DNA Damage Response Modulation: Disulfiram appears to influence the cell's response to DNA damage, not by preventing the initial damage itself, but by facilitating DNA repair and reducing the accumulation of unrepaired lesions.
  • Aberrant Mitosis Suppression: By reducing aberrant mitosis, disulfiram helps prevent the propagation of genetic errors and maintains genomic stability in the regenerating intestinal epithelium.

Key Results

  • Improved Survival: Disulfiram treatment significantly prolonged survival in mice subjected to lethal total-body irradiation (TBI), extending survival time by an average of 3-7 days.
  • Reduced Intestinal Injury: In total-abdominal irradiation (TAI) models, disulfiram pretreatment led to a higher survival rate (56.3% vs. 81.25% mortality in vehicle-treated mice). Histological analysis showed a threefold increase in surviving crypts and a significant restoration of villus height in disulfiram-treated mice.
  • Enhanced Crypt Regeneration: Disulfiram treatment increased the number of regenerated crypts across a range of irradiation doses (10, 12, and 14 Gy). Proliferation assays (BrdU) showed that while disulfiram initially inhibited proliferation within 24 hours, it significantly promoted crypt regeneration later, reaching three times the level of control mice by 84 hours post-irradiation.
  • ISC Preservation: Disulfiram significantly reduced the loss of Lgr5-GFP+ intestinal stem cells by over 70% at 48 hours post-irradiation. Lineage tracing experiments showed a 1.6-fold increase in progeny from Lgr5+ stem cells in disulfiram-treated mice.
  • Mitigated DNA Damage and Aberrant Mitosis: Disulfiram treatment led to a significant decrease in γ-H2AX-positive cells (indicating unrepaired DNA DSBs) and a 40% reduction in aberrant mitosis in crypts 24 hours after irradiation.

Limitations and Future Work

  • Oral Bioavailability: While oral disulfiram showed some efficacy, its effect was not as pronounced as intraperitoneal injection, suggesting potential issues with oral bioavailability that warrant further investigation.
  • Species and Strain Variation: The authors acknowledge that radioprotective effects can vary between species and strains. Further studies in larger animal models (canines, minipigs, nonhuman primates) are recommended to assess disulfiram's potential for clinical translation.
  • Fractionated Radiotherapy: The study focused on single high-dose irradiation. Future work should investigate whether disulfiram is also protective against conventionally fractionated radiotherapy, especially in the context of abdominal and pelvic tumors.
  • Mechanism of DSB Repair: While disulfiram appears to facilitate DNA repair, the specific pathways involved require further elucidation.
  • PUMA-Deficient Mice: The finding that disulfiram promoted crypt regeneration even in PUMA-deficient mice suggests that its protective mechanisms extend beyond simply preventing early apoptosis, pointing to other pathways that need exploration.

Summary updated

Abstract

Radiation-induced intestinal injury (RIII) occurs after high doses of radiation exposure. RIII restricts the therapeutic efficacy of radiotherapy in cancer and increases morbidity and mortality in nuclear disasters. Currently, there is no approved agent for the prevention or treatment of RIII. Here, we reported that the disulfiram, an FDA-approved alcohol deterrent, prolonged the survival in mice after lethal irradiation. Pretreatment with disulfiram inhibited proliferation within 24 h after irradiation, but improved crypt regeneration at 3.5 days post-irradiation. Mechanistically, disulfiram promoted Lgr5<sup>+</sup> intestinal stem cells (ISCs) survival and maintained their ability to regenerate intestinal epithelium after radiation. Moreover, disulfiram suppresses DNA damage accumulation, thus inhibits aberrant mitosis after radiation. Unexpectedly, disulfiram treatment did not inhibit crypt cell apoptosis 4 h after radiation and the regeneration of crypts from PUMA-deficient mice after irradiation was also promoted by disulfiram. In conclusion, our findings demonstrate that disulfiram regulates the DNA damage response and survival of ISCs through affecting the cell cycle. Given its radioprotective efficacy and decades of application in humans, disulfiram is a promising candidate to prevent RIII in cancer therapy and nuclear accident.
BibTeX
@inproceedings{yuan2022disulfiram,
  author = {Qingwen Yuan and Renjun Peng and Huijie Yu and Sinian Wang and Zhongmin Chen and Suhe Dong and Wěi Li and Bo Cheng and Qisheng Jiang and Yuwen Cong and Fengsheng Li and Changzheng Li},
  title = {{Disulfiram Protects Against Radiation-Induced Intestinal Injury in Mice}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.852669},
}
Figure